Overview

Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma

Status:
Active, not recruiting

Trial end date:
2024-11-01

Target enrollment:

Participant gender:

Summary

This study aims to determine which of 3 drug combinations best reduces the size of tumour prior to surgery for advanced melanoma and prevents the recurrence of melanoma after surgery.

Phase:

Phase 2

Details

Lead Sponsor:

Melanoma Institute Australia

Collaborators:

Merck Sharp & Dohme Corp.
Novartis

Treatments:

Dabrafenib
Pembrolizumab
Trametinib